More generally, our results suggest that therapeutic targets in EC related to angiogenic, inflammatory and Αβ clearance pathways deserve prioritisation in the search for treatments able to slow or prevent the onset of AD. The gene discussed is PPIB; the disease is Alzheimer disease.